BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54

BMO Capital analyst Malcolm Hoffman maintains LB Pharmaceuticals (NASDAQ:LBRX) with a Outperform and raises the price target from $46 to $54.